|
Aug 12
|
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
|
|
Aug 11
|
Analysts Are Upgrading Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results
|
|
Aug 9
|
Intellia Therapeutics Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 8
|
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
|
|
Aug 8
|
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Market Research 2025 | Key Players Include Intellia Therapeutics, Renowned for NTLA-2001 in Phase III Development, Leveraging CRISPR/Cas9
|
|
Aug 7
|
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
|
|
Aug 7
|
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
|
|
Jul 31
|
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
|
|
Jul 31
|
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
|
|
Jul 30
|
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
|
|
Jul 3
|
Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data
|
|
Jun 27
|
3 Promising Genomics Stocks to Keep an Eye On in 2025
|
|
Jun 25
|
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
|
|
Jun 23
|
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
|
|
Jun 21
|
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?
|
|
Jun 18
|
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
|
|
Jun 17
|
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
|
|
Jun 17
|
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
|
|
Jun 15
|
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
|
|
Jun 4
|
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
|